Literature DB >> 32016817

The effects simultaneous inhibition of dipeptidyl peptidase-4 and P2X7 purinoceptors in an in vivo Parkinson's disease model.

Nida Jamali-Raeufy1, Zahra Mojarrab2,3, Tourandokht Baluchnejadmojarad2, Mehrdad Roghani4, Javad Fahanik-Babaei2, Mina Goudarzi2.   

Abstract

Loss of dopaminergic neurons following Parkinson's disease (PD) diminishes quality of life in patients. The present study was carried out to investigate the protective effects of simultaneous inhibition of dipeptidyl peptidase-4 (DPP-4) and P2X7 purinoceptors in a PD model and explore possible mechanisms. The 6-hydroxydopamine (6-OHDA) was used as a tool to establish PD model in male Wister rats. The expressions of SIRT1, SIRT3, mTOR, PGC-1α, PTEN, P53 and DNA fragmentation were evaluated by ELISA assay. Behavioral impairments were determined using apomorphine-induced rotational and narrow beam tests. Dopamine synthesis and TH-positive neurons were detected by tyrosine hydroxylase (TH) immunohistochemistry. Neuronal density was determined by Nissl staining. OHDA-lesioned rats exhibited behavioral impairments that reversed by BBG, lin and lin + BBG. We found significant reduced levels of SIRT1, SIRT3, PGC-1α and mTOR in both mid brain and striatum from OHDA-lesioned rats that reversed by BBG, lin and lin + BBG. Likewise, significant increased levels of PTEN and P53 were found in both mid brain and striatum from OHDA-lesioned rats that was reversed by BBG, lin and lin + BBG. TH-positive neurons and neuronal density were markedly reduced OHDA-lesioned rats that reversed by BBG, lin and lin + BBG. Collectively, our results showed protective effects of simultaneous inhibition of DPP-4 and P2X7 purinoceptors in a rat model of PD can be linked to targeting SIRT1/SIRT3, PTEN-mTOR pathways. Moreover, our findings demonstrated that simultaneous inhibition of DPP-4 and P2X7 purinoceptors might have stronger effect on mitochondrial biogenesis compared to only one.

Entities:  

Keywords:  Dipeptidyl peptidase-4 inhibitor; P2X7 purinoceptor antagonist; Parkinson’s disease; SIRT1; SIRT3; mTOR

Year:  2020        PMID: 32016817     DOI: 10.1007/s11011-020-00538-x

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  29 in total

Review 1.  Protective effects and mechanisms of sirtuins in the nervous system.

Authors:  Feng Zhang; Suping Wang; Li Gan; Peter S Vosler; Yanqin Gao; Michael J Zigmond; Jun Chen
Journal:  Prog Neurobiol       Date:  2011-09-10       Impact factor: 11.685

2.  Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model.

Authors:  Tourandokht Baluchnejadmojarad; Mehrdad Roghani; Mohammad Reza Jalali Nadoushan; Maryam Bagheri
Journal:  Phytother Res       Date:  2009-01       Impact factor: 5.878

3.  SIRT3 Acts as a Neuroprotective Agent in Rotenone-Induced Parkinson Cell Model.

Authors:  Jing-Yi Zhang; Yong-Ning Deng; Meng Zhang; Hua Su; Qiu-Min Qu
Journal:  Neurochem Res       Date:  2016-04-06       Impact factor: 3.996

4.  SIRT3 attenuates MPTP-induced nigrostriatal degeneration via enhancing mitochondrial antioxidant capacity.

Authors:  Lei Liu; Carina Peritore; Jessica Ginsberg; Merve Kayhan; Gizem Donmez
Journal:  Neurochem Res       Date:  2015-01-03       Impact factor: 3.996

5.  Hypericum Perforatum Hydroalcoholic Extract Mitigates Motor Dysfunction and is Neuroprotective in Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson's Disease.

Authors:  Zahra Kiasalari; Tourandokht Baluchnejadmojarad; Mehrdad Roghani
Journal:  Cell Mol Neurobiol       Date:  2015-06-29       Impact factor: 5.046

Review 6.  Therapeutic role of sirtuins in neurodegenerative disease and their modulation by polyphenols.

Authors:  Marjan Ajami; Hamidreza Pazoki-Toroudi; Hamed Amani; Seyed Fazel Nabavi; Nady Braidy; Rosa Anna Vacca; Atanas Georgiev Atanasov; Andrei Mocan; Seyed Mohammad Nabavi
Journal:  Neurosci Biobehav Rev       Date:  2016-11-30       Impact factor: 8.989

7.  mTORC1 and p53: clash of the gods?

Authors:  Paul Hasty; Zelton Dave Sharp; Tyler J Curiel; Judith Campisi
Journal:  Cell Cycle       Date:  2013-01-01       Impact factor: 4.534

Review 8.  Stages in the development of Parkinson's disease-related pathology.

Authors:  Heiko Braak; Estifanos Ghebremedhin; Udo Rüb; Hansjürgen Bratzke; Kelly Del Tredici
Journal:  Cell Tissue Res       Date:  2004-08-24       Impact factor: 5.249

Review 9.  Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.

Authors:  Ronald Deumens; Arjan Blokland; Jos Prickaerts
Journal:  Exp Neurol       Date:  2002-06       Impact factor: 5.330

10.  SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson's disease.

Authors:  Preeti Singh; Peter S Hanson; Christopher M Morris
Journal:  BMC Neurosci       Date:  2017-06-02       Impact factor: 3.288

View more
  2 in total

1.  The effects of lithium chloride and cathodal/anodal transcranial direct current stimulation on conditional fear memory changes and the level of p-mTOR/mTOR in PFC of male NMRI mice.

Authors:  Mojgan Hamdami; Solmaz Khalifeh; Nida Jamali-Raeufy; Mohammad Nasehi
Journal:  Metab Brain Dis       Date:  2020-11-21       Impact factor: 3.584

2.  Activating SIRT-1 Signalling with the Mitochondrial-CoQ10 Activator Solanesol Improves Neurobehavioral and Neurochemical Defects in Ouabain-Induced Experimental Model of Bipolar Disorder.

Authors:  Bidisha Rajkhowa; Sidharth Mehan; Pranshul Sethi; Aradhana Prajapati; Manisha Suri; Sumit Kumar; Sonalika Bhalla; Acharan S Narula; Abdulrahman Alshammari; Metab Alharbi; Nora Alkahtani; Saeed Alghamdi; Reni Kalfin
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.